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A B S T R A C T
Mechanisms that preserve and maintain the cellular proteome are associated with long life and healthy aging.
Oxidative damage is a signiﬁcant contributor to perturbation of proteostasis and is dealt with by the cell through
regulation of antioxidants, protein degradation, and repair of oxidized amino acids. Methionine sulfoxide
reductase A (MsrA) repairs oxidation of free- and protein-bound methionine residues through enzymatic
reduction and is found in both the cytosol and the mitochondria. Previous studies in Drosophila have shown
that increasing expression of MsrA can extend longevity. Here we test the eﬀects of increasing MsrA on
longevity and healthy aging in two transgenic mouse models. We show that elevated expression of MsrA
targeted speciﬁcally to the cytosol reduces the rate of age-related death in female mice when assessed by
Gompertz analysis. However, neither cytosolic nor mitochondrial MsrA overexpression extends lifespan when
measured by log-rank analysis. In mice with MsrA overexpression targeted to the mitochondria, we see evidence
for improved insulin sensitivity in aged female mice. With these and our previous data, we conclude that the
increasing MsrA expression in mice has diﬀerential eﬀects on aging and healthy aging that are dependent on the
target of its subcellular localization.
1. Introduction
There is growing evidence that maintenance of cellular proteostasis
is a signiﬁcant determinant of both longevity and healthy aging across
the animal kingdom [1,2]. In this regard, the cellular response to
oxidative stress is of importance because oxidative damage to cellular
proteins can compromise protein function leading to cellular dysfunc-
tion, pathological manifestation of disease, and mortality [3]. While
much of the focus on cellular proteostasis has highlighted removal of
damaged proteins through the ubiquitin-proteasome system or autop-
hagy, some forms of protein oxidative damage can be eliminated by
endogenous cellular repair systems in vivo. Repairing or refolding
damaged proteins might be viewed as an energetically favorable means
of proteostasis to the cell rather than complete destruction and
replacement of damaged proteins [2]. Of the small group of known
endogenous protein repair mechanisms, the methionine sulfoxide
reductases (Msr) can uniquely repair oxidation of free- and protein-
bound methionine residues through enzymatic reduction [4,5]. Beyond
direct methionine oxidation repair, Msr may also more broadly protect
proteins by acting as a part of a free-radical sink wherein easily
oxidized (and subsequently reduced by Msr) methionine residues act
as targets of oxidative stress and thereby protect other amino acids
from damage [6].
In eukaryotes, Msr exist as two main isoforms, MsrA and MsrB
(which are further divided into 3 subclasses in mammals), each with
speciﬁcity to diﬀerent epimers of methionine oxidation. Because it was
discovered prior to MsrB, the majority of studies regarding the
biological signiﬁcance of Msr activity have focused on the MsrA
isoform. In terms of aging, both MsrA and MsrB1 now appear to be
dispensable for mouse longevity [7,8], though there was historical
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suggestion that mice lacking MsrA are short-lived [9]. However, MsrA
has been reported to be required for longevity extension associated
with either dietary restriction or genetic modulation of the daf-2 gene
in C. elegans [10,11]. On the other hand, increasing levels of MsrA, but
not of MsrB, has been shown to signiﬁcantly increase lifespan in
Drosophila [12–14]. One key diﬀerence between these isoforms is that
MsrA is found in both the cytosol and the mitochondria of mammalian
cells, whereas MsrB subclasses have discrete subcellular locations [15].
Both mitochondrial and cytosolic forms of MsrA are translated from a
single gene with localization being dependent on alternative translation
initiation sites [16].
The generation of the ﬁrst transgenic mouse models designed to
express increased levels of MsrA was reported in 2010 [17]. We and
others have found that increasing MsrA expression in mice can be
protective in mouse disease models, but that this protection is
dependent on the subcellular location to which increased MsrA
expression is targeted. Increased levels of MsrA in its native myristoy-
lated form in the cytosol protect against cardiac ischemia/reperfusion
injury in a mouse Langendorﬀ model [18]. In contrast, overexpression
of MsrA in the mitochondria has no eﬀect on this cardiac injury.
Conversely, increasing MsrA in the mitochondria, but not the cytosol,
prevents insulin resistance in mice fed a high fat/high sugar diet [19].
This metabolic beneﬁt under metabolic stress is attributed, at least in
part, to a shift toward preferential use of fatty acid oxidation as energy
substrates in mice with mitochondria-targeted overexpression of MsrA.
With our previous data showing that increasing levels and/or
activity of MsrA may be beneﬁcial for some aspects of healthy aging
in mice as well as reports that overexpressing MsrA can increase
Drosophila lifespan [12,14], our main goal in this study was to
determine the eﬀect of increasing MsrA expression on mouse lifespan.
Because MsrA is natively found in both cytosol and mitochondria in
mammals, our study used two novel MsrA transgenic mouse models
designed to target increased MsrA expression to either the cytosol or
the mitochondria. This allowed us to determine not only whether
overexpressing MsrA in mice would increase lifespan or slow aging but
also to determine whether any diﬀerences were driven by the sub-
cellular localization of this enzyme.
2. Results
To determine the eﬀect of high levels of MsrA on mammalian aging,
we assessed the lifespan of mice with MsrA overexpression targeted to
either the cytosol (TgCyto MsrA) or to the mitochondria (TgMito
MsrA). The generation and general characterization of these mice has
been previously reported [17–19]. Mice for this study were produced
using a hemizygous breeding scheme resulting in both transgenic and
wild-type (control) littermates. TgCyto MsrA and TgMito MsrA mice
were maintained as independent breeding lines and for assessment of
longevity with control mice from each line being pooled for compar-
ison. Although the Log Rank analysis of survival allows one to
determine if an experimental manipulation aﬀects the overall survival
curve of a group of animals, the Gompertz analysis allows one to study
more in depth the eﬀect of a manipulation on the survival of a
population because Gompertz pointed out that the rate of mortality
increases exponentially with age [20]. This exponential increase occurs
after an initial period of age-independent mortality pointed out by
Makeham (e.g. neonatal deaths and childhood deaths due to infectious
diseases), and so we have the Gompertz-Makeham Law, often referred
to as a Gompertz analysis. When mortality is plotted on a semi-
logarithmic scale, the x-intercept, or the initial hazard rate at time zero,
gives an estimate of the age-independent mortality while the slope
gives an estimate of the rate of aging (Fig. 1). Using this means of
analysis, we found that the slope of the TgCyto MsrA mice is
signiﬁcantly smaller than that of the control (p=0.009) but not diﬀerent
from TgMito MsrA mice (p=0.07). Thus, TgCyto MsrA mice exhibit a
decreased rate of aging compared to control mice. In contrast, TgMito
MsrA mice do not signiﬁcantly diﬀer from TgCyto MsrA mice or control
mice. Interestingly, TgCyto MsrA mice have a signiﬁcantly higher x-
intercept than control mice (p=0.02), but not higher than that of
TgMito MsrA mice (p=0.07). A possible interpretation of this ﬁnding is
that TgCyto MsrA mice have a larger early age-independent mortality,
but those mice that survive the early period age at a slower rate than
control mice. In contrast, TgMito MsrA mice do not signiﬁcantly diﬀer
from control or TgCyto MsrA mice in either parameter.
We also show in Fig. 1 the survival curves of all three lines of mice.
These data show that increasing levels of MsrA in either the cytosol or
mitochondria had no signiﬁcant eﬀect on lifespan of female mice when
assessed by either the standard log-rank test (p=0.52) or by Gehan-
Breslow test (p=0.37) which gives more weight to earlier deaths. Mean,
median and maximum (90%) survival data are presented in Table 1.
Fig. 1. Increased MsrA in the cytosol slows the rate of aging A. Gompertz slopes
calculated across lifespan for Control (solid line), TgCyto MsrA (dashed line) and TgMito
MsrA (dotted line). For each line, (slope, x-intercept) are as follows: control (0.01,
−13.93), TgCyto MsrA (0.0062, −10.51), TgMito MsrA (0.0092, −13.22). B. Log Rank
survival curve for Control (closed circle), TgCyto MsrA (open square) and TgMito MsrA
(open triangle) female mice. Each symbol represents the natural death of an individual
mouse.
Table 1
Longevity parameters (in days) of mouse strains used in study.
n Mean (d ±SEM) Median (d) 90% (d)
Control 35 835 ( ± 22) 857 974
TgCyto MsrA 31 789 ( ± 36) 789 1018
TgMito MsrA 23 865 ( ± 28) 886 1008
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We tested the median survivorship of each transgenic line against that
of the control mice and found no signiﬁcant eﬀect for either TgCyto
MsrA (p=0.08) or TgMito MsrA (p=0.43). As can be seen from Fig. 1,
the TgCyto MsrA and TgMito MsrA curves appeared to suggest slightly
greater maximum (90%) survivorship than that of control mice. Using
the Fisher's Exact Test method to determine eﬀect on maximum
lifespan, we found that neither TgCyto MsrA (p=0.09) or TgMito
MsrA (p=0.08) diﬀered from control mice [21]. Maximum lifespan as
determined by Boschloo's Exact test, also described by Wang and
Allison, showed a signiﬁcant increase in maximum lifespan of TgCyto
MsrA mice in relation to control mice (p=0.018), but no diﬀerence
between TgMito MsrA and control mice (0.09). These data then
highlight both the importance of Gompertz analysis of lifespan as well
as potential deﬁciencies that may occur when only a single method of
longevity analysis is used.
Previous studies have suggested that transgene expression driven
by certain promoter elements can decline with age in mouse models
[22]. Here, we show that young TgCyto MsrA and TgMito MsrA mice
express high levels of MsrA in kidney (relatively high in endogenous
MsrA) and skeletal muscle (relatively low in endogenous MsrA) and
that these are largely maintained with age (Fig. 2). Similar results were
found in other tissues including liver and brain (data not shown). As
previously reported, the level of overall MsrA expression is higher in
TgMito MsrA mice than in TgCyto MsrA mice [17,19]. Increasing MsrA
expression in either transgenic model does not signiﬁcantly alter MsrB
expression suggesting no compensatory changes in regulation of this
Msr isoform. However, MsrB levels signiﬁcantly decline with age to the
approximately the same degree in all lines of mice.
As measures of healthspan, we addressed whether increased MsrA
expression could improve the maintenance of metabolic homeostasis in
aging mice including body composition and glucose metabolism. In
these studies, young females were between 6 and 9 months and old
females between 24 and 30 months of age. Old mice did not diﬀer in
body weight compared to young mice. Among age-matched mice we
found no eﬀect of genotype on body weight (Fig. 3). Despite the lack of
eﬀect on overall weight, we did ﬁnd that aging promoted a shift in body
composition with age; fat mass was signiﬁcantly reduced and fat-free
mass was signiﬁcantly increased in old mice relative to that found in
young mice (Fig. 3). Again, genotype had no signiﬁcant eﬀect on either
of these parameters; that is, body composition of TgCyto MsrA and
TgMito MsrA mice did not diﬀer from age-matched control mice.
We recently reported that TgCyto MsrA and TgMito MsrA mice do
not diﬀer from control mice in glucose tolerance or insulin sensitivity
when measured in young mice maintained on normal rodent chow
[19]. However, we also showed that TgMito MsrA mice showed
preserved insulin sensitivity when they were maintained on a high
fat/high sugar diet. We interpret these ﬁndings as evidence that
mitochondrial MsrA overexpression does not grossly aﬀect glucose
metabolism, but rather protects against the dysregulation of glucose
metabolism associated with metabolic stress. We show here that old
TgMito MsrA mice have increased sensitivity to insulin as measured by
insulin tolerance test (Fig. 4). In particular, at the 90 and 120 min
points of this test, TgMito MsrA mice show hypoglycemia due to
injection of insulin whereas blood glucose levels begin to return to
normal in control and TgCyto MsrA mice. This outcome in TgMito
MsrA mice likely suggests increased relative hepatic insulin sensitivity
in that there is a sustained insulin-mediated suppression of hepatic
glucose production. In line with this, we found no eﬀect of MsrA
expression on glucose tolerance, the outcome of which is driven largely
by insulin release and insulin-mediated glucose uptake in muscle.
Fasting concentrations of insulin in the plasma were not markedly
diﬀerent between control and TgMito MsrA mice (control =0.59 ±
Fig. 2. MsrA and MsrB1 expression changes with age and transgenic expression. A. Representative immunoblot of kidney and muscle of young (6–9 months) and old (24–30 months)
control (Co), TgCyto MsrA (TgC) and TgMito MsrA (TgM) mice. B. Quantiﬁcation of proteins measure in A. Bars indicated mean protein level for indicated group; error bars indicated
standard error.
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0.17 ng/mL, TgMito MsrA=0.34 ± 0.08 ng/mL). These data suggest
that increased mitochondria-targeted MsrA protects against age-re-
lated declines in insulin signaling, perhaps most importantly those that
regulate hepatic glucose metabolism.
3. Discussion
We show here that overexpression of the protein repair enzyme
MsrA in the cytosol, but not the mitochondria, can slow the rate of
aging in the mouse. However, our data also show no signiﬁcant eﬀect
on maximum or median lifespan in mice that overexpress MsrA in
either the cytosol or mitochondria. These data are in contrast to the
studies in Drosophila showing that the increased expression of either
endogenous or bovine MsrA does signiﬁcantly extend lifespan [12,14].
Our data is important because it indicates that the eﬀect of MsrA













































Fig. 3. Age, but not transgenic MsrA expression, alters body composition. Body weight, fat mass and fat-free mass from young (6–9 months) and old (24–30 months) control, TgCyto
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Fig. 4. Mitochondrial-, but not cytosolic-, targeted MsrA overexpression improves insulin sensitivity in old mice. A. Insulin tolerance tests and calculated areas under curves. B. Glucose
tolerance tests and calculated areas under curve. For both, each symbol represents mean value ( ± standard error) for Control (closed circle), TgCyto MsrA (open square) and TgMito
MsrA (open triangle) female mice for indicated tests. Bars indicate mean values ( ± standard error) for indicated measurements. Asterisk indicates signiﬁcant eﬀect of genotype.
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directly to mammals. It is also important to note that we also did not
see any eﬀect of knocking out MsrA on the lifespan of mice [7]. A
possible explanation for the inability of overexpression of MsrA to
extend the mouse maximal lifespan is the diﬀerence in causes of death
in ﬂies and mice. The most likely primary cause of death in mice is
cancer, but the causes of mortality in Drosophila are uncertain [23].
This might suggest that the primary cause of death in C57BL/6 mice
(i.e. mostly lymphoma) may be largely unaﬀected by MsrA. However,
MsrA has been shown to impact the progression of several diseases
known to be accelerated by the aging process, including metabolic
dysfunction, neurological diseases, breast cancer and retinal defects in
mammals [19,24–27]. Moreover, we showed that increasing levels of
MsrA in mice is protective against cardiac ischemia/reperfusion and
metabolic dysfunction caused by obesity and/or aging [18,19]. One
possibility is that oxidative stress plays a greater role in the modulation
of these age-related physiological functions and does not largely drive
death and/or longevity in mice. In the future, it will be necessary to
delineate the roles that MsrA plays among multiple factors that aﬀect
healthy aging if not lifespan in mice.
Our data suggest physiological beneﬁts with regard to healthy aging
in mammals that are associated with increasing levels of MsrA. The
decreased rate of aging in TgCyto MsrA mice as measured by Gompertz
analysis and increased insulin sensitivity in aged TgMito MsrA mice are
consistent with the interpretation of improved healthspan. In particu-
lar, using Gompertz analysis of longevity allowed us to determine a
signiﬁcant diﬀerence in the rate of aging despite no clear eﬀect on
overall survival of TgCyto MsrA mice when measured by Log Rank.
These basic conclusions are summarized in Fig. 5. While we are unable
to do so with the models used here, it would be of interest to test
whether global overexpression of MsrA (i.e. in both cytosol and
mitochondria) might extend both beneﬁts on aging mice.
The aging process is associated with signiﬁcant alterations in
metabolic function in mammals, including dysfunctional glucose
homeostasis, development of insulin resistance and alterations in
energy utilization. In humans, the prevalence of diabetes is signiﬁcantly
higher in aged populations, even after accounting for changes in body
mass, and is one of the most common co-morbidities in the elderly
[28]. Thus, preventing metabolic dysfunction is likely to signiﬁcantly
improve healthy aging. Here and elsewhere, we have now deﬁned a role
for MsrA in regulating insulin sensitivity in response to both high fat
diet and aging [19,24]. As recently reported, MsrA preferentially
repairs methionine sulfoxide in unfolded proteins [29], and we might
predict that the presence of mitochondrial MsrA plays an important
role in the quality control during mitochondrial protein import.
Following this idea, loss of MsrA in both the cytosol and mitochondria
is associated with mitochondrial dysfunction [27]. Determination of




Mice with MsrA overexpression targeted to the cytosol (TgCyto
MsrA) or mitochondria (TgMito MsrA) were bred in the animal
facilities of the Audie L. Murphy Veterans Administration Hospital of
the South Texas Veteran's Health Care System. Individual transgenic
lines were maintained with hemizygous (i.e., Tg/wt x wt/wt) breeding
plan to generate both transgenic and wild-type control littermates. All
strains of mice are maintained in the C57BL/6J genetic background.
Mice were genotyped for presence of transgene, and overexpression
was conﬁrmed by immunoblot. For longevity studies, female mice were
used and all cages of mice were maintained at a density of 4 mice per
cage beginning at approximately 3 months of age. For littermate cages
originally < 4, females of the same approximate age from diﬀerent
cages were supplemented to achieve a ﬁnal number of 4 per cage. Mice
were housed under barrier conditions using micro-isolator cages and
were fed ad libitum a standard NIH-31 chow diet (Harlan Teklad,
Madison, WI). Mice were maintained on a 12-h dark/light cycle in the
animal vivarium. The mice in the survival groups were monitored daily
and maintained until natural death. A separate cohort of mice were
maintained under similar conditions to generate old animals for
metabolic/healthspan assessments. All procedures involving mice were
approved by the Subcommittee for Animal Studies at the Audie L.
Murphy Veterans Administration Hospital at San Antonio and the
Institutional Animal Care and Use Committee at the University of
Texas Health Science Center at San Antonio.
4.2. Metabolic assessment
Glucose and insulin tolerance tests were performed after overnight
fast (18:00–09:00 the following day) and then injection of either
glucose (1.5 g kg−1) or insulin (0.75 U kg−1) intraperitoneally as pre-
viously described [19,24]. A handheld OneTouch Ultra glucometer
(LifeScan, Inc., Milpitas, CA) was used to measure whole blood glucose
at each indicated time point. For all other metabolic assessments,
animals were transferred to the San Antonio Nathan Shock Center
Healthspan and Functional Assessment core facility. Body composition
was assessed in non-anesthetized mice by Quantitative Magnetic
Resonance imaging (QMRi) using an EchoMRI 3-in-1 composition
analyzer (Echo Medical Systems, Houston TX). Insulin concentrations
were determined in plasma from fasting animals using kit from Crystal
Fig. 5. Scheme of the major conclusions from this study.
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Chem (Downers Grove, IL).
4.3. Immunoblotting
Tissue samples were collected from mice euthanized by CO2
inhalation followed by cervical dislocation. All samples were frozen in
liquid N2 and stored at −80 °C until use. Protein extracts were prepared
in RIPA buﬀer with added phosphatase and protease inhibitors
(Thermo Scientiﬁc, Rockford, IL, USA). Standard protocols were used
for separation of proteins by SDS-PAGE and transfer to PVDF
membrane. After incubation with primary antibodies to MsrA and
MsrB1 (Abcam, Cambridge MA) or actin (Sigma, St. Louis MO),
alkaline phosphatase-conjugated secondary antibodies and ECL re-
agent were used to detect bands which were quantiﬁed using ImageJ
software.
4.4. Statistical analysis
Longevity curves were determined using the Kaplan-Meyer estima-
tor and analyzed for diﬀerence using log-rank and Gehan-Breslow
tests. Maximum lifespan was analyzed using the Wang-Allison test [21]
which uses a Boschloo's Exact test to test diﬀerences between groups in
their survival of maximum 10% of subjects with the longest lifespan.
The Gompertz mortality analysis of lifespan was conducted in order to
model the hazard rate variation in time. The Gompertz distribution,
with shape parameter a and scale parameter b, has instantaneous age-
speciﬁc mortality (hazard rate) given by h(t)=a exp(bt), and it is known
to provides a remarkably close ﬁt to adult mortality. The Gompertz
parameters a and b are the initial rate of mortality and the rate of
increase in the hazard for mortality (i.e. the mortality rate), respec-
tively. Log hazard function dependence on time is linear, with intercept
log(a) and slope b, and can be easily visualized on a 2d Gompertz plot.
Kaplan–Meier estimation, Gompertz parametric modeling, log-rank
testing for diﬀerences between survival curves, and Boschloo testing for
diﬀerence in extreme survival were performed with speciﬁc functions
implemented in the R packages survival, eha and Exact. Quantile
regression, as described in Koenker [30] and implemented in the R
package quantreg, was used to estimate and compare mean, median,
and extreme quartile survival times for each group. For glucose and
insulin tolerance tests, areas under curves were calculated using the
trapezoid method. Diﬀerences among groups were determined by
ANOVA. For all other tests, two way ANOVA were used to test for
diﬀerences in age and genotype. Post-hoc analysis was performed using
the method of Holm-Sidak.
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